Primary antibody	Product ID & Company
Mouse anti-AC-α-Tubulin	Sigma
Rabbit anti-DNAI2	17533-1-AP Proteintech
Rabbit anti-DNAH1	HPA036806 Sigma
Secondary antibody	**Product ID & Company**
Goat anti rabbit IgG H&L	Abcam
Goat anti mouse IgG H&L	Abcam

Primer name	Base sequence
chr17–42979917-Reverse	GTAGCTTGCCGCATCAGTCA
chr17–42979917- Forward	GTTGCAGAACAGCTGGAAGA
chr17–42978905-Reverse	CAGAGAATCCTGCTGGACTA
chr17–42978905- Forward	CAGTCAGCTATCGCTGTTGT

Table S1. Antibody& Primer List





Figure S1. Sanger sequencing validation of the *CCDC103* mutation.

Note: Red arrows indicate the mutation.

cDNA mutation	Protein alteration	Mutation type	Allele frequency in ExAC Browser	Function prediction
CCDC103: NM_213607: Exon 3:c.161_162del	p.His55Serfs*9	Exonic deletion, frameshift	0	SIFT NA PolyPhen-2 NA Mutation-Assessor NA
CCDC103: NM_213607: Exon 4:c.461A>C	p.His154Pro	Missence mutation	0.0013	SIFT T PolyPhen-2 P Mutation-Assessor M

NA, not available. T: tolerant. P: possibly damaging. M: medium.

Table S2. Biallelic *CCDC103* Mutations Identified in the patient with PCD.

Gene	Chromosome location GRCh37/hg19	Nucleic acid changes	Amino acid changes	Transcripts	Exons Introns	Heterozygosity	Allele frequency in ExAC Browser	Pathogenicity
DNAH9	chr17:11603195	c.5020G>A	p.G1674R	NM_001372	Exon 23	Het	0	NA
DNAH9	chr17:11757372	c.9560A>G	p.N3187S	NM_001372	Exon 50	Het	0.000058	NA

Table S3. Potentially deleterious variants found in affected individual.

Het, Heterozygous; NA, not available.



NM_001372: c.5020G>A, p.G1674R



NM_001372: c.9560A>G, p.N3187S



Figure S2. Sanger sequencing validation of the *DNAH5* mutation.

Note: Red arrows indicate the mutation.